- Home
- PCSA vs LFLY Comparison
PCSA vs LFLY Comparison
Compare PCSA & LFLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- LFLY
- Stock Information
- Founded
- PCSA 2011
- LFLY 2010
- Country
- PCSA United States
- LFLY United States
- Employees
- PCSA N/A
- LFLY N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- LFLY Computer Software: Prepackaged Software
- Sector
- PCSA Health Care
- LFLY Technology
- Exchange
- PCSA Nasdaq
- LFLY Nasdaq
- Market Cap
- PCSA 4.3M
- LFLY 5.0M
- IPO Year
- PCSA N/A
- LFLY N/A
- Fundamental
- Price
- PCSA $0.83
- LFLY $1.59
- Analyst Decision
- PCSA Strong Buy
- LFLY Strong Buy
- Analyst Count
- PCSA 2
- LFLY 2
- Target Price
- PCSA $5.00
- LFLY $7.59
- AVG Volume (30 Days)
- PCSA 938.6K
- LFLY 45.8K
- Earning Date
- PCSA 10-30-2024
- LFLY 11-07-2024
- Dividend Yield
- PCSA N/A
- LFLY N/A
- EPS Growth
- PCSA N/A
- LFLY N/A
- EPS
- PCSA N/A
- LFLY N/A
- Revenue
- PCSA N/A
- LFLY $35,868,000.00
- Revenue This Year
- PCSA N/A
- LFLY N/A
- Revenue Next Year
- PCSA N/A
- LFLY N/A
- P/E Ratio
- PCSA N/A
- LFLY N/A
- Revenue Growth
- PCSA N/A
- LFLY N/A
- 52 Week Low
- PCSA $0.81
- LFLY $1.10
- 52 Week High
- PCSA $9.28
- LFLY $5.10
- Technical
- Relative Strength Index (RSI)
- PCSA 34.88
- LFLY 61.51
- Support Level
- PCSA $0.81
- LFLY $1.10
- Resistance Level
- PCSA $0.99
- LFLY $1.80
- Average True Range (ATR)
- PCSA 0.13
- LFLY 0.17
- MACD
- PCSA -0.03
- LFLY 0.05
- Stochastic Oscillator
- PCSA 3.34
- LFLY 80.23
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About LFLY Leafly Holdings Inc.
Leafly Holdings Inc operates an online cannabis information resource platform. It offers cannabis retailers and brands subscription-based marketplace listings that provide its cannabis audience with information, reviews, menus, and ordering and delivery options through legal retailers.